Giorgio Valabrega

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial

Anna Passarelli, Michele Bartoletti, Alberto Farolfi, Maria Lucia Iacovino et autres

BACKGROUND: The phosphatase and tensin homolog-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) pathway is frequently altered in gynecological tumors, notably in endometrial cancer where PIK3CA mutations are found in nearly half of patients. Despite this, evidence of clinical activity of PI3K inhibitors in …

it, my, us, ch (code pays fourni par la source)

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

Matthew A. Powell, Sharad Ghamande, L Hanker, Destin Black et autres

OBJECTIVE: Dostarlimab+carboplatin-paclitaxel followed by dostarlimab maintenance demonstrated statistically significant and clinically meaningful benefits in progression-free and overall survival in the overall population of primary advanced/recurrent endometrial cancer versus chemotherapy alone in Part 1 of the phase 3 ENGOT-EN6-NSGO/GOG-3031/RUBY trial (NCT03981796). Part 2 …

us, de, dk, ca, cz, ps, es, gb, nl, be, by, my, fi, it (code pays fourni par la source)

Spatial transcriptomic analysis reveals coordinated gene expression in ovarian clear cell carcinoma and adjacent endometriosis in UK and Japanese patients

Takafumi Kuroda, Gaia Giannone, Darren Ennis, Hasan Mirza et autres

Abstract Purpose Ovarian clear cell carcinoma (OCCC) is strongly associated with endometriosis and shows geographic variation in incidence. We investigated whether OCCC and adjacent endometriosis exhibit distinct transcriptional states and whether these patterns differ between United Kingdom (UK) and Japanese cohorts. Experimental …

jp, gb, it (code pays fourni par la source)

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial

Matthew A. Powell, Henrik Roed, Lyndsay Willmott, David Cibula et autres

OBJECTIVE: Dostarlimab+carboplatin-paclitaxel (CP) demonstrated significant improvement in progression-free survival (PFS) and clinically meaningful improvement in overall survival (OS) vs CP alone among patients with dMMR/MSI-H primary advanced/recurrent endometrial cancer (EC) in Part 1 of the randomized phase 3 RUBY trial (NCT03981796). We …

us, dk, cz, it, de, nl, ua, se, ca (code pays fourni par la source)

RAINFOL-03 (ENGOT-EN-31/GOG-3128): A global, phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice of chemotherapy in patients with endometrial cancer after platinum-based chemotherapy and programmed death-ligand 1 inhibition.

Antonio Gonzalez Martin, Elena Ioana Braicu, Pallavi Kumar, Kosei Hasegawa et autres

TPS5646 Background: Patients with recurrent endometrial cancer (EC) whose disease progresses after platinum-based chemotherapy (PBC) and programmed death (ligand) 1 [PD-(L)1] inhibition have a poor prognosis and limited, ineffective treatment options. Single-agent chemotherapy in this setting has been associated with low objective …

es, de, us, jp, ca, br, lt, sg, it, gb (code pays fourni par la source)

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group

Martina Arcieri, Sandro Pignata, Domenica Lorusso, Anna Fagotti et autres

On 24 June 2025, the MITO (Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group hosted a webinar entitled "TRUST on the Ring" to discuss the TRUST trial 1,2 , presented at ASCO (American Society of Clinical Oncology) 2025 conference. Eight …

it, us, jp, cz (code pays fourni par la source)

Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial.

B Monk, Ignacio Romero, David M. O’Malley, Corina Martinez Mena et autres

5565 Background: GIS is a key component of a companion diagnostic assay for determining homologous recombination deficiency (HRD) status to identify pts with aOC who may benefit from maintenance therapy. While the standard GIS cutoff to classify tumors as homologous recombination-deficient (HRd) …

us, es, be, fi, it, fr, de (code pays fourni par la source)

Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).

Lucy Gilbert, Benoit You, Alexander Olawaiye, Chel Hun Choi et autres

5503 Background: Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist that increases tumor sensitivity to chemotherapy-induced apoptosis. The phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer (PROC) recently reported statistically significant results for the dual primary …

ca, fr, in, us, kr, it, au, be, es, hu, gb (code pays fourni par la source)

Macrophage Activation Syndrome Following Atezolizumab in Advanced Non-Small-Cell Lung Cancer: A Case Report

Andrea Caglio, Emma Pisciotta, Gaetano Lacidogna, Mariele Gatto et autres

Immunotherapy with immune checkpoint inhibitors (ICIs) has profoundly transformed the therapeutic landscape of lung cancer. Although ICIs are generally associated with a more favorable toxicity profile compared with traditional chemotherapy, rare and potentially severe immune-related adverse events (irAEs) may occur, sometimes posing …

it, by (code pays fourni par la source)

Current and around-the-corner therapies in platinum-resistant ovarian cancer: an insight into the ROSELLA study

Valentina Tuninetti, Giorgio Valabrega

Regional Audit and Feedback Intervention to Improve Quality of Care in Ovarian Cancer Treatment: The Easy-Net Experience

Elisa Piovano, Annamaria Ferrero, Giovannino Ciccone, Marco Camanni et autres

PURPOSE: In 2009, a regional audit on ovarian cancer in the Regional Cancer Care Network (RCCN) of Piemonte (Italy) documented that patients were widely distributed across different treatment centers, with evidence of suboptimal care. We present the re-audit and feedback (A&F) intervention …

it (code pays fourni par la source)

Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma

Tao Han, Lujun Chen, Ning Liu, Yingchen Han et autres

Portal vein tumor thrombus (PVTT) is among the most lethal complications of hepatocellular carcinoma (HCC), yet its molecular mechanisms and immune features remain poorly characterized. To address this gap, we performed a comprehensive multi-omics analysis of 99 specimens from 47 patients, integrating …

cn, de, us, jp, it (code pays fourni par la source)